Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Shares Outstanding readings, the most recent being $126.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 1.71% year-over-year to $126.6 million, compared with a TTM value of $126.6 million through Dec 2025, up 1.71%, and an annual FY2025 reading of $126.6 million, up 1.71% over the prior year.
  • Shares Outstanding hit $126.6 million in Q4 2025 for Apellis Pharmaceuticals, roughly flat from $126.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $126.6 million in Q4 2025, with the low at $80.4 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $118.0 million (2023), compared with a mean of $112.3 million.
  • The sharpest move saw Shares Outstanding soared 115125.78% in 2021, then increased 1.71% in 2025.
  • Year by year, Shares Outstanding stood at $97.5 million in 2021, then increased by 13.58% to $110.8 million in 2022, then grew by 7.93% to $119.6 million in 2023, then grew by 4.13% to $124.5 million in 2024, then increased by 1.71% to $126.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $126.6 million, $126.5 million, and $126.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.